SCHEMBL23395657

SCHEMBL23395657

CCc1ncccc1-c1cc2ccc(OC)cc2o1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTPN1 P18031 1/20 0.49
▸ APP P05067 4/20 0.47
▸ RAB9A P51151 4/20 0.42
▸ NPC1 O15118 3/20 0.42
▸ ADRA2A P08913 1/20 0.42
▸ ADRA2B P18089 1/20 0.42
▸ ADRA2C P18825 1/20 0.42
▸ KMT2A Q03164 1/20 0.41
▸ F2RL3 Q96RI0 3/20 0.41
▸ KDM4E B2RXH2 3/20 0.41
▸ ALDH1A1 P00352 3/20 0.41
▸ HPGD P15428 2/20 0.41
▸ GAA P10253 2/20 0.41
▸ MAPT P10636 2/20 0.41
▸ GLA P06280 1/20 0.41
▸ PKM P14618 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ ATM Q13315 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26292178 0.88 RAB9A (0.42) PTPN1APPRAB9ANPC1KDM4E
SCHEMBL23893560 0.82 KDM4E (0.36) PTPN1APPRAB9ANPC1F2RL3
SCHEMBL23395722 0.82 ALDH1A1 (0.36) PTPN1APPRAB9ANPC1F2RL3
SCHEMBL23395574 0.82 PTPN1 (0.51) PTPN1APPRAB9ANPC1KMT2A
SCHEMBL23395599 0.82 PDE4D (0.54) PTPN1APPCYP19A1
SCHEMBL26291695 0.80 ALDH1A1 (0.40) PTPN1APPRAB9ANPC1KMT2A
SCHEMBL26291692 0.80 RAB9A (0.38) PTPN1APPRAB9ANPC1KMT2A
SCHEMBL23395686 0.80 APP (0.35) PTPN1APPRAB9ANPC1F2RL3
SCHEMBL30568050 0.79 PTPN1 (0.53) PTPN1APPRAB9ANPC1KMT2A
SCHEMBL20473134 0.79 PTPN1 (0.53) PTPN1APPRAB9ANPC1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11753387-B2 Compounds for optically active devices Johnson & Johnson Surgical Vision, Inc. (US) 2023-09-12 — — US disclosed
US-11753387-B2 Compounds for optically active devices Johnson & Johnson Surgical Vision, Inc. (US) 2023-09-12 — — US disclosed
EP-3889135-B1 COMPOUNDS FOR OPTICALLY ACTIVE DEVICES AMO Ireland (IE) 2023-08-02 — — EP disclosed
EP-3889135-A1 COMPOUNDS FOR OPTICALLY ACTIVE DEVICES Merck Patent GmbH (DE) 2021-10-06 — — EP disclosed
EP-3583092-B1 COMPOUNDS FOR OPTICALLY ACTIVE DEVICES MERCK PATENT GMBH (DE) 2021-05-26 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11753387-B2 Compounds for optically active devices PDE6C, PDE6A, PDE6D PTPN1 4651/4885APP 899/4885RAB9A 1119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback